AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Revolutionary ovarian cancer rapid test available Q4 2022
The company exports mobile surgery equipment to over 100 countries from Pune
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The partners also aim to expand their work to Latin America for the first time
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Subscribe To Our Newsletter & Stay Updated
